Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Benjamin

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
Nature Reviews. Clinical Oncology|May 31, 2023
The FDA's latest draft guidance on accelerated approvals - one step forward, two steps back?David J Benjamin, Mark P Lythgoe
Clinical Medicine Insights. Oncology|February 7, 2024
Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022David J Benjamin, Arash Rezazadeh Kalebasty
Urology|February 21, 2025
The Genitourinary Medical Oncology Workforce in the United StatesDavid J Benjamin, Arash Rezazadeh Kalebasty
Targeted Oncology|December 17, 2024
FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic StrategiesDavid J Benjamin, Alain C Mita
Rare Tumors|July 19, 2023
Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapiesDavid J Benjamin, Arash Rezazadeh Kalebasty
JAMA Internal Medicine|July 5, 2022
Prostate Cancer Screening at US Cancer CentersDavid J Benjamin, Arash Rezazadeh Kalebasty
The Lancet. Oncology|April 3, 2025
Sexual health and reproductive toxicity from cancer therapiesDavid J Benjamin, Mark P Lythgoe
The Lancet. Oncology|March 1, 2023
Modernising the US FDA's Accelerated Approval pathwayDavid J Benjamin, Mark P Lythgoe
European Urology Oncology|October 17, 2024
Pairing the Right Individual with the Right Regimen: Patient Selection Criteria in the Treatment of Advanced Urothelial CarcinomaDavid J Benjamin, Arash Rezazadeh Kalebasty
Translational Cancer Research|June 17, 2026
Quality of life with EV-302 in advanced urothelial carcinoma: lessons and implicationsDavid J Benjamin, Arash Rezazadeh Kalebasty
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Nature Reviews. Clinical Oncology|May 31, 2023
The FDA's latest draft guidance on accelerated approvals - one step forward, two steps back?David J Benjamin, Mark P Lythgoe
Clinical Medicine Insights. Oncology|February 7, 2024
Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022David J Benjamin, Arash Rezazadeh Kalebasty
Urology|February 21, 2025
The Genitourinary Medical Oncology Workforce in the United StatesDavid J Benjamin, Arash Rezazadeh Kalebasty
Targeted Oncology|December 17, 2024
FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic StrategiesDavid J Benjamin, Alain C Mita
Rare Tumors|July 19, 2023
Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapiesDavid J Benjamin, Arash Rezazadeh Kalebasty
JAMA Internal Medicine|July 5, 2022
Prostate Cancer Screening at US Cancer CentersDavid J Benjamin, Arash Rezazadeh Kalebasty
The Lancet. Oncology|April 3, 2025
Sexual health and reproductive toxicity from cancer therapiesDavid J Benjamin, Mark P Lythgoe
The Lancet. Oncology|March 1, 2023
Modernising the US FDA's Accelerated Approval pathwayDavid J Benjamin, Mark P Lythgoe
European Urology Oncology|October 17, 2024
Pairing the Right Individual with the Right Regimen: Patient Selection Criteria in the Treatment of Advanced Urothelial CarcinomaDavid J Benjamin, Arash Rezazadeh Kalebasty
Translational Cancer Research|June 17, 2026
Quality of life with EV-302 in advanced urothelial carcinoma: lessons and implicationsDavid J Benjamin, Arash Rezazadeh Kalebasty
Pageof 9